Top

Published in:

Open Access 01-05-2016 | Laboratory Investigation

The effects of antiepileptic drugs on the growth of glioblastoma cell lines

Authors: Ching-Yi Lee, Hung-Yi Lai, Angela Chiu, She-Hung Chan, Ling-Ping Hsiao, Shih-Tseng Lee

Published in: Journal of Neuro-Oncology | Issue 3/2016

Abstract

To determine the effects of antiepileptic drug compounds on glioblastoma cellular growth, we exposed glioblastoma cell lines to select antiepileptic drugs. The effects of selected antiepileptic drugs on glioblastoma cells were measured by MTT assay. For compounds showing significant inhibition, cell cycle analysis was performed. Statistical analysis was performed using SPSS. The antiepileptic compounds selected for screening included carbamazepine, ethosuximide, gabapentin, lamotrigine, levetiracetam, magnesium sulfate, oxcarbazepine, phenytoin, primidone, tiagabine, topiramate, valproic acid, and vigabatrin. Dexamethasone and temozolomide were used as a negative and positive control respectively. Our results showed temozolomide and oxcarbazepine significantly inhibited glioblastoma cell growth and reached IC₅₀ at therapeutic concentrations. The other antiepileptic drugs screened were unable to reach IC₅₀ at therapeutic concentrations. The metabolites of oxcarbazepine were also unable to reach IC_50. Dexamethasone, ethosuximide, levetiracetam, and vigabatrin showed some growth enhancement though they did not reach statistical significance. The growth enhancement effects of ethosuximide, levetiracetam, and vigabatrin found in the study may indicate that these compounds should not be used for prophylaxis or short term treatment of epilepsy in glioblastoma. While valproic acid and oxcarbazepine were effective, the required dose of valproic acid was far above that used for the treatment of epilepsy and the metabolites of oxcarbazepine failed to reach significant growth inhibition ruling out the use of oral oxcarbazepine or valproic acid as monotherapy in glioblastoma. The possibility of using these compounds as local treatment is a future area of study.

CBTRUS (2011) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. Source: Central Brain Tumor Registry of the United States, Hinsdale www.cbtrus.org. Accessed 13 Aug 2012

DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114–123CrossRefPubMed

Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL (2007) Epidemiology of brain tumors. Neurol Clin 25:867–890CrossRefPubMed

Rowland LP, Pedley TA (eds) (2010) Merritt’s neurology, 12th edn. Lippincott, Williams, & Wilkins, Philadelphia

Smith KC (2010) The management of seizures in brain tumor patients. J Neurosci Nurs 1:28–37CrossRef

Chabner BC (ed) (2008) Harrison’s manual of oncology, 1st edn. McGraw-Hill Companies Inc., New York

Chamberlain MC, Kormanik PA (1998) Practical guidelines for the treatment of malignant gliomas. West J Med 169:114–120

Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635–644CrossRefPubMed

Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (eds) (2012) Harrison’s principles of internal medicine, 18th edn. McGraw-Hill Companies Inc., New York

10.

National Comprehensive Cancer Network (2011) Central nervous system cancers. NCCN clinical practice guidelines in oncology version 2

11.

Samuels MA, Ropper AH (eds) (2010) Samuels’s manual of neurologic therapeutics, 8th edn. Lippincott, Williams, & Wilkins, Philadelphia

12.

Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis Treatment and Follow-up. Ann Oncol 21(Suppl 5):v190–v193CrossRefPubMed

13.

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507CrossRefPubMed

14.

Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L (2006) Medical management of patients with brain tumors. J Neurooncol 80:313–332CrossRefPubMed

15.

Kargiotis O, Markoula S, Kyritsis AP (2001) Epilepsy in the cancer patient. Cancer Chemother Pharmacol 67:489–501CrossRef

16.

Van Breemen MSM, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430CrossRefPubMed

17.

Sperling MR, Ko J (2006) Seizures and brain tumors. Semin Oncol 33:333–341CrossRefPubMed

18.

Blaheta RA, Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22(5):492–511CrossRefPubMed

19.

Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY (2007) Medical management of brain tumor patients. Neurol Clin 25:1035–1071CrossRefPubMed

20.

Michelucci R (2006) Optimizing therapy of seizures in neurosurgery. Neurology 67(Suppl 4):S14–S18CrossRefPubMed

21.

Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A et al (2009) Epilepsy in cerebral glioma: timing of appearance and histological correlations. J Neurooncol 93:395–400CrossRefPubMed

22.

Rossetti AO, Stupp R (2010) Epilepsy in brain tumor patients. Curr Opin Neurol 23:603–609CrossRefPubMed

23.

Schaller B, Ruegg SJ (2003) Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 44(9):1223–1232CrossRefPubMed

24.

Vecht CJ, Van Breemen M (2006) Optimizing therapy of seizures in patients with brain tumors. Neurology 67(Suppl 4):S10–S13CrossRefPubMed

25.

Tsai HC, Wei KC, Tsai CN, Huang YC, Chen PY, Chen SM et al (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg 26(3):347–354CrossRefPubMed

26.

De Salvo M, Maresca G, D’Angano I, Marchese R, Stigliano A, Gagliassi R et al (2011) Temozolomide induced c-Myc-mediated apoptosis via akt signaling in mgmt expressing glioblastoma cells. Int J Radiat Biol 87(5):518–533CrossRefPubMed

27.

Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–457CrossRefPubMed

28.

Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ et al (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285(52):40461–40471CrossRefPubMedPubMedCentral

29.

Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF et al (2011) Overcoming temozolomide resistance in glioblastoma via dual inhibition of nad⁺ biosynthesis and base excision repair. Cancer Res 71:2308–2317CrossRefPubMedPubMedCentral

30.

Das A, Banik NL, Ray SK (2008) Modulatory effect of acetazolomide and dexamethasone on temozolomide mediated apoptosis in human glioblastoma T98G and U87MG cells. Cancer Invest 26:352–358CrossRefPubMed

31.

Moroz MA, Huang R, Kochetkov T, Shi W, Thaler H, de Stanchina E et al (2011) Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin Cancer Res 17:3282–3292CrossRefPubMedPubMedCentral

32.

Toutain PL (2002) Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS PharmSci 4(4):1–29CrossRef

33.

de Lange ECM, Ravenstijn PGM, Groenendaal D, van Steeg TJ (2005) Towards the prediction of cns drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 7(3):E532–E542CrossRefPubMedPubMedCentral

34.

Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? Clin Pharmacokinet 45(11):1061–1075CrossRefPubMed

35.

Micromedex^® Healthcare Series [Internet database] Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Updated periodically

36.

Brunton LL, Chabner BA, Knollmann BC (2011) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill Companies Inc, New York

37.

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds) (2011) Pharmacotherapy: a pathophysiologic approach, 8th edn. McGraw-Hill Companies Inc., New York

38.

Katzung BG, Masters SB, Trevor AJ (eds) (2012) Basic & clinical pharmacology, 12th edn. McGraw-Hill Companies Inc., New York

39.

Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE et al (2007) Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159–170CrossRefPubMed

40.

Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP (2010) Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-Oncology 12(4):328–340CrossRefPubMedPubMedCentral

41.

Wagner S, van Gool S, Hau P, Pietsch T, Peters O, Wolff J (2009) Valproic acid as a potent substance for increasing efficacy of topoisomerase i inhibitors. Turk J Cancer 39(5):104–109

42.

El Sharkawi FZ, El Shemy HA, Khaled HM (2014) Possible anticancer activity of rosuvastatine, doxazosin, repaglinide, and oxcarbazepin. Asian Pac J Cancer Prev 15:199–203CrossRefPubMed

43.

Schmidt D, Elger CE (2004) What in the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5:627–635CrossRefPubMed

44.

Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr (2005) Evolving anticancer drug valproic acid: insights in the mechanism and clinical studies. Med Res Rev 25(4):383–397CrossRefPubMed

45.

Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N (2008) A phase II clinical trail of oral valroic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl Oncol 1(3):141–147CrossRefPubMedPubMedCentral

46.

Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, Jager E (2007) Valproic Acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97:177–182CrossRefPubMedPubMedCentral

47.

Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Fekrazad MH, Lee FC, Rabinowitz I, Ravindranathan M, Jones DV Jr (2014) A phase I protocol of hydralazine and valproic acid in advanced previously treated solid cancers. Transl Oncol 7(3):349–354CrossRefPubMedCentral

Title: The effects of antiepileptic drugs on the growth of glioblastoma cell lines
Authors: Ching-Yi Lee
Hung-Yi Lai
Angela Chiu
She-Hung Chan
Ling-Ping Hsiao
Shih-Tseng Lee
Publication date: 01-05-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2056-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The effects of antiepileptic drugs on the growth of glioblastoma cell lines

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

In vivo multiphoton tomography and fluorescence lifetime imaging of human brain tumor tissue

Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas

The modified lateral supraorbital approach for tumors of the petroclival junction extending into the anterior cerebellopontine area

Positron emission tomography of high-grade gliomas

Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI

Optic toxicity in radiation treatment of meningioma: a retrospective study in 213 patients